{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:29:09Z","timestamp":1784546949219,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04062-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:35Z","timestamp":1751354195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg"],"prefix":"10.1186","volume":"25","author":[{"given":"Meng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"4","key":"4062_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatology: J Eur Association Study Liver. 2006;45(4):529\u201338.","journal-title":"J Hepatology: J Eur Association Study Liver"},{"key":"4062_CR2","doi-asserted-by":"crossref","unstructured":"Collaborators GHB. Global, regional, and National burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019[J]. Lancet Gastroenterology & Hepatology. 2022;7(9):796\u2013829.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"4062_CR3","unstructured":"Organization WH. Global Hepatitis Report, 2017[M]. 2017."},{"issue":"4","key":"4062_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"11\u201312","key":"4062_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/apt.12990","volume":"40","author":"CS Coffin","year":"2014","unstructured":"Coffin CS, Rezaeeaval M, Pang JX, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos (t) Ide analogue therapy[J]. Aliment Pharmacol Ther. 2014;40(11\u201312):1262\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4062_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jvh.12418","volume":"23","author":"V Kim","year":"2016","unstructured":"Kim V, Abreu RM, Nakagawa DM, et al. Pegylated interferon Alfa for chronic hepatitis B: systematic review and meta-analysis[J]. J Viral Hepatitis. 2016;23(3):154\u201369.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"4062_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"2","key":"4062_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","volume":"18","author":"J Hou","year":"2020","unstructured":"Hou J, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with Entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol. 2020;18(2):457\u201367.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"4062_CR9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu DI, Wang G, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus[J]. J Viral Hepatitis. 2019;26(10):1146\u201355.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"4062_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","volume":"139","author":"J Liu","year":"2010","unstructured":"Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study[J]. Gastroenterology. 2010;139(2):474\u201382.","journal-title":"Gastroenterology"},{"key":"4062_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.colsurfb.2019.02.040","volume":"178","author":"H Zheng","year":"2019","unstructured":"Zheng H, Lang Y, Yu J, et al. Affinity binding of aptamers to agarose with DNA tetrahedron for removal of hepatitis B virus surface antigen[J]. Colloids Surf B. 2019;178:80\u20136.","journal-title":"Colloids Surf B"},{"issue":"34","key":"4062_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0076-6879(74)34009-8","volume":"34","author":"I Parikh","year":"1974","unstructured":"Parikh I, March S, Cuatercasas P. Topics in the methodology of substitution reactions with agarose.[J]. Methods Enzymol. 1974;34(34):77\u2013102.","journal-title":"Methods Enzymol"},{"issue":"3","key":"4062_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/01.ATV.4.3.276","volume":"4","author":"S Yokoyama","year":"1984","unstructured":"Yokoyama S, Hayashi R, Kikkawa T, et al. Specific sorbent of Apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.[J]. Arteriosclerosis. 1984;4(3):276\u201382.","journal-title":"Arteriosclerosis"},{"issue":"9","key":"4062_CR14","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1517\/13543784.9.9.2017","volume":"9","author":"N Braun","year":"2000","unstructured":"Braun N, Bosch T, Immunoadsorption. Current status and future Developments[J]. Expert Opin Investig Drugs. 2000;9(9):2017\u201338.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"4062_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-022-04009-w","volume":"26","author":"C Ronco","year":"2022","unstructured":"Ronco C, Bellomo R. Hemoperfusion: technical aspects and state of the art[J]. Crit Care. 2022;26(1):135.","journal-title":"Crit Care"},{"issue":"3","key":"4062_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000514187","volume":"51","author":"W Cheng","year":"2022","unstructured":"Cheng W, Luo Y, Wang H, et al. Survival outcomes of hemoperfusion and Hemodialysis versus Hemodialysis in patients with end-stage renal disease: a systematic review and meta-analysis[J]. Blood Purif. 2022;51(3):213\u201325.","journal-title":"Blood Purif"},{"key":"4062_CR17","doi-asserted-by":"crossref","unstructured":"Ghannoum M, Bouchard J, Nolin TD, et al. Hemoperfusion for the treatment of poisoning: technology, determinants of poison clearance, and application in clinical practice, 2014[C]. Wiley Online Library; 2014.","DOI":"10.1111\/sdi.12246"},{"key":"4062_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fimmu.2018.00145","volume":"9","author":"A J\u00fcnemann","year":"2018","unstructured":"J\u00fcnemann A, Hohberger B, Rech J, et al. Agonistic autoantibodies to the \u03b22-adrenergic receptor involved in the pathogenesis of open-angle glaucoma[J]. Front Immunol. 2018;9:145.","journal-title":"Front Immunol"},{"issue":"1","key":"4062_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","volume":"15","author":"A Kronbichler","year":"2016","unstructured":"Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review[J]. Autoimmun Rev. 2016;15(1):38\u201349.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4062_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.transci.2009.10.001","volume":"42","author":"O Hequet","year":"2010","unstructured":"Hequet O, Le QH, Rigal D, et al. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis[J]. Transfus Apheresis Sci. 2010;42(1):3\u201310.","journal-title":"Transfus Apheresis Sci"},{"issue":"3","key":"4062_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1744-9987.2006.00336.x","volume":"10","author":"T Bosch","year":"2006","unstructured":"Bosch T, Gahr S, Belschner U, et al. Direct adsorption of low-density lipoprotein by DALI\u2010LDL\u2010Apheresis: results of a prospective long\u2010term multicenter follow\u2010up covering 12 291 sessions[J]. Therapeutic Apheresis Dialysis. 2006;10(3):210\u20138.","journal-title":"Therapeutic Apheresis Dialysis"},{"key":"4062_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10529-011-0840-0","volume":"34","author":"RA Nassar","year":"2012","unstructured":"Nassar RA, Browne EP, Chen J, et al. Removing human immunodeficiency virus (HIV) from human blood using immobilized heparin[J]. Biotechnol Lett. 2012;34:853\u20136.","journal-title":"Biotechnol Lett"},{"key":"4062_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.msec.2017.03.047","volume":"76","author":"J Ciejka","year":"2017","unstructured":"Ciejka J, Wolski K, Nowakowska M, et al. Biopolymeric nano\/microspheres for selective and reversible adsorption of coronaviruses[J]. Mater Sci Engineering: C. 2017;76:735\u201342.","journal-title":"Mater Sci Engineering: C"},{"issue":"1","key":"4062_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000167011","volume":"27","author":"RH Tullis","year":"2009","unstructured":"Tullis RH, Duffin RP, Handley HH, et al. Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients[J]. Blood Purif. 2009;27(1):64\u20139.","journal-title":"Blood Purif"},{"key":"4062_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jchromb.2016.03.004","volume":"1017","author":"B Chen","year":"2016","unstructured":"Chen B, Ye Q, Zhou K, et al. Adsorption and separation of HCV particles by novel affinity aptamer-functionalized adsorbents[J]. J Chromatogr B. 2016;1017:174\u201381.","journal-title":"J Chromatogr B"},{"issue":"3\u20134","key":"4062_CR26","first-page":"286","volume":"38","author":"S B\u00fcttner","year":"2015","unstructured":"B\u00fcttner S, Koch B, Dolnik O, et al. Extracorporeal virus elimination for the treatment of severe Ebola virus disease-first experience with lectin affinity plasmapheresis[J]. Blood Purif. 2015;38(3\u20134):286\u201391.","journal-title":"Blood Purif"},{"key":"4062_CR27","doi-asserted-by":"publisher","first-page":"109372","DOI":"10.1016\/j.jfluchem.2019.109372","volume":"227","author":"VA Likholobov","year":"2019","unstructured":"Likholobov VA, P\u2019Yanova LG, Danilenko AM, et al. Protein-functionalized fluorocarbon hemosorbent for binding to hepatitis B surface antigen[J]. J Fluorine Chem. 2019;227:109372.","journal-title":"J Fluorine Chem"},{"issue":"1","key":"4062_CR28","first-page":"1269063","volume":"2018","author":"Z Han","year":"2018","unstructured":"Han Z, Lu X, Tang Y, et al. The removal of HBV in plasma by extracorporeal immunoadsorption from plasma: A potential therapy of hepatitis B Patients[J]. Biomed Res Int. 2018;2018(1):1269063.","journal-title":"Biomed Res Int"},{"key":"4062_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11901-019-00494-w","volume":"18","author":"L Mak","year":"2019","unstructured":"Mak L, Seto W, Yuen M. Future therapies for functional cure of chronic HBV: review of investigational drugs in phase 1 and 2 development[J]. Curr Hepatol Rep. 2019;18:503\u201311.","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"4062_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","volume":"388","author":"G Dusheiko","year":"2023","unstructured":"Dusheiko G, Agarwal K, Maini MK. New approaches to chronic hepatitis B[J]. N Engl J Med. 2023;388(1):55\u201369.","journal-title":"N Engl J Med"},{"issue":"21","key":"4062_CR31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"M Yuen","year":"2022","unstructured":"Yuen M, Lim S, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med. 2022;387(21):1957\u201368.","journal-title":"N Engl J Med"},{"key":"4062_CR32","doi-asserted-by":"crossref","unstructured":"Gane E, Lim Y, Tangkijvanich P, et al. Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients, 2020[C]. Elsevier BV. The Journal's web site is located at http:\/\/www.elsevier.com\u2026, 2020.","DOI":"10.1016\/S0168-8278(20)30647-4"},{"issue":"8","key":"4062_CR33","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet M, P\u00e2ntea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, Tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection Na\u00efve to nucleos (t) Ide therapy[J]. Gastroenterology. 2020;158(8):2180\u201394.","journal-title":"Gastroenterology"},{"key":"4062_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosissup.2015.02.007","volume":"18","author":"J Dittrich-Riediger","year":"2015","unstructured":"Dittrich-Riediger J, Schatz U, Hohenstein B, et al. Adverse events of lipoprotein apheresis and immunoadsorption at the apheresis center at the university hospital Dresden[J]. Atherosclerosis Supplements. 2015;18:45\u201352.","journal-title":"Atherosclerosis Supplements"},{"issue":"2","key":"4062_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1525-1594.2000.06476.x","volume":"24","author":"T Bosch","year":"2000","unstructured":"Bosch T, Lennertz A, Schmidt B, et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood[J]. Artif Organs. 2000;24(2):81\u201390.","journal-title":"Artif Organs"},{"issue":"12","key":"4062_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1525-1594.2003.07200.x","volume":"27","author":"C Otto","year":"2003","unstructured":"Otto C, Kern P, Bambauer R, et al. Efficacy and safety of a new whole-blood low\u2010density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia[J]. Artif Organs. 2003;27(12):1116\u201322.","journal-title":"Artif Organs"},{"key":"4062_CR37","doi-asserted-by":"crossref","unstructured":"Zhao L, Y K Z. Manipulation of pore structure during manufacture of agarose microspheres for bioseparation[J]. Eng Life Sci, 2020,20(11).","DOI":"10.1002\/elsc.202000023"},{"issue":"11","key":"4062_CR38","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/ccr3.3140","volume":"8","author":"F Wen","year":"2020","unstructured":"Wen F, Wu X, Liao R, et al. Protein A immunoadsorption combination with immunosuppressive therapy improves neuropsychiatric systemic lupus erythematosus: A case report[J]. Clin Case Rep. 2020;8(11):2158\u201362.","journal-title":"Clin Case Rep"},{"issue":"5","key":"4062_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/v9050125","volume":"9","author":"S Schreiner","year":"2017","unstructured":"Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus CccDNA formation\u2014and beyond?[J]. Viruses. 2017;9(5):125.","journal-title":"Viruses"},{"issue":"1","key":"4062_CR40","first-page":"935295","volume":"2013","author":"Y Kondo","year":"2013","unstructured":"Kondo Y, Ninomiya M, Kakazu E, et al. Hepatitis B surface antigen could contribute to the Immunopathogenesis of hepatitis B virus infection[J]. Int Sch Res Notices. 2013;2013(1):935295.","journal-title":"Int Sch Res Notices"},{"issue":"8","key":"4062_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"4062_CR42","doi-asserted-by":"crossref","unstructured":"Gane E, Lim Y, Cloutier D, et al. Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results, 2021[C]. Elsevier BV. The Journal's web site is located at http:\/\/www.elsevier.com\u2026, 2021.","DOI":"10.1016\/S0168-8278(20)30647-4"},{"key":"4062_CR43","unstructured":"Agarwal K, Yuen R, Wedemeyer H, et al. A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection, 2021[C]. Elsevier BV. The Journal's web site is located at http:\/\/www.elsevier.com\u2026, 2021."},{"key":"4062_CR44","doi-asserted-by":"crossref","unstructured":"Yuen M, Asselah T, Jacobson IM, et al. Efficacy and safety of the SiRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos (t) Ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial[J]. The Lancet Gastroenterology & Hepatology. 2023;8(9):790\u2013802.","DOI":"10.1016\/S2468-1253(23)00148-6"},{"key":"4062_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","volume":"30","author":"C Dembek","year":"2018","unstructured":"Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination[J]. Curr Opin Virol. 2018;30:58\u201367.","journal-title":"Curr Opin Virol"},{"key":"4062_CR46","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0168-8278(23)00453-1","volume":"78","author":"M Yuen","year":"2023","unstructured":"Yuen M, Lim Y, Lim TH, et al. Safety and efficacy of VIR-2218 with or without pegylated interferon Alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up[J]. J Hepatol. 2023;78:S11\u20132.","journal-title":"J Hepatol"},{"key":"4062_CR47","unstructured":"Kennedy P, Fung S, Buti M et al. Efficacy and safety of SiRNA JNJ-73763989, capsid assembly modulator-E (CAM-E) JNJ-56136379, and nucleos (t) Ide analogs (NA) with pegylated interferon alpha-2a (PEGIFN-\u03b12a) added in immune-tolerant patients with chronic hepatitis B virus (HBV) infection: interim results from the phase 2 REEF-IT study[J]. 2023."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04062-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:39Z","timestamp":1751354199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04062-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal study was performed with the permission of the Institutional Animal Care and Use Committee (IACUC) of Hubei Topgene Xinsung Technology Limited Company (XS-2021-001-01). Euthanasia\/sacrifice methods: overdose of anaesthetic. Name of anaesthetic: Pentobarbital Sodium. Injection dosage: 100\u2013200\u00a0mg\/kg. Method: Intravenous injection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}